- Home
- ALZN vs ONVO Comparison
ALZN vs ONVO Comparison
Compare ALZN & ONVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALZN
- ONVO
- Stock Information
- Founded
- ALZN 2016
- ONVO 2007
- Country
- ALZN United States
- ONVO United States
- Employees
- ALZN N/A
- ONVO N/A
- Industry
- ALZN Medicinal Chemicals and Botanical Products
- ONVO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ALZN Health Care
- ONVO Health Care
- Exchange
- ALZN Nasdaq
- ONVO Nasdaq
- Market Cap
- ALZN 7.0M
- ONVO 6.7M
- IPO Year
- ALZN 2021
- ONVO N/A
- Fundamental
- Price
- ALZN $1.11
- ONVO $0.36
- Analyst Decision
- ALZN Strong Buy
- ONVO
- Analyst Count
- ALZN 1
- ONVO 0
- Target Price
- ALZN $32.00
- ONVO N/A
- AVG Volume (30 Days)
- ALZN 174.7K
- ONVO 250.2K
- Earning Date
- ALZN 12-31-2024
- ONVO 02-06-2025
- Dividend Yield
- ALZN N/A
- ONVO N/A
- EPS Growth
- ALZN N/A
- ONVO N/A
- EPS
- ALZN N/A
- ONVO N/A
- Revenue
- ALZN N/A
- ONVO $103,000.00
- Revenue This Year
- ALZN N/A
- ONVO $59.08
- Revenue Next Year
- ALZN N/A
- ONVO $18.24
- P/E Ratio
- ALZN N/A
- ONVO N/A
- Revenue Growth
- ALZN N/A
- ONVO N/A
- 52 Week Low
- ALZN $1.06
- ONVO $0.32
- 52 Week High
- ALZN $15.06
- ONVO $1.74
- Technical
- Relative Strength Index (RSI)
- ALZN 34.55
- ONVO 38.97
- Support Level
- ALZN $1.16
- ONVO $0.42
- Resistance Level
- ALZN $1.33
- ONVO $0.39
- Average True Range (ATR)
- ALZN 0.09
- ONVO 0.05
- MACD
- ALZN 0.01
- ONVO -0.01
- Stochastic Oscillator
- ALZN 17.86
- ONVO 12.50
About ALZN Alzamend Neuro Inc.
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.
About ONVO Organovo Holdings Inc.
Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases.